A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 312-322

  Gradishar, William J ^a   Kaklamani, Virginia ^b   Sahoo, Tarini P ^c   Lokanatha, Dasappa ^d   Raina, Vinod ^e   Bondarde, Shailesh ^f   Jain, Minish ^g   Ro, Sunhee Kwon ^h   Lokker, Nathalie A ^h   Schwartzberg, Lee ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

^d Kidwai Institute of Oncology   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f Shatabadi Hospital   (India)

^g Ruby Hall Clinic ^*  (India)

^h ONYX PHARMACEUTICALS   (United States)

ⁱ WEST CLINIC   (United States)

Author keywords

Breast cancer; HER2 negative; Kinase inhibitor

Indexed keywords

PACLITAXEL; PLACEBO; SORAFENIB;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BACKACHE; BRAZIL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; INDIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PACLITAXEL; PHENYLUREA COMPOUNDS; RECEPTOR, ERBB-2;

EID: 84872110165     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.005     Document Type: Article

References (30)

1. B.P. Schneider, and K.D. Miller Angiogenesis of breast cancer J Clin Oncol 23 2005 1782 1790
2. M.A. Cobleigh, V.K. Langmuir, and G.W. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 2003 117 124
3. H.J. Burstein, A.D. Elias, and H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
4. G. Bianchi, S. Loibl, and C. Zamagni Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
5. C.H. Barrios, M.C. Liu, and S.C. Lee Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer Breast Cancer Res Treat 121 2010 121 131
6. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
7. K.D. Miller, L.I. Chap, and F.A. Holmes Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799
8. D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
9. N.J. Robert, V. Dieras, and J. Glaspy RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
10. A.M. Brufsky, S. Hurvitz, and E. Perez RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 2011 10.1200/JCO.2010.34.1255
11. J. Baselga, J. Segalla, and H. Roché Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer J Clin Oncol 30 2012 1484 1491
12. C. Hudis, K. Tauer, and R. Hermann Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) J Clin Oncol 29 Suppl. 2011 Abstr. 1009
13. G. Mariani, O. Burdaeva, and L. Roman A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer: FM-B07-01 Trial Eur J Cancer 47 Suppl. 2 2011 Abstr. 17LBA
14. K.T. Flaherty, J. Schiller, and L.M. Schuchter A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel Clin Cancer Res 14 2008 4836 4842
15. K.T. Flaherty, M. Brose, and L. Schuchter Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [Abstract] J Clin Oncol 22 Suppl. 2004 Abstr. 7507
16. A.D. Seidman, D. Berry, and C. Cirrincione Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 2008 1642 1649
17. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
18. T.R. Fleming, and B.A. Richardson Some design issues in trials of microbicides for the prevention of HIV infection J Infect Dis 190 2004 666 674
19. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
20. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
21. M.E. Lacouture, S. Wu, and C. Robert Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 2008 1001 1011
22. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892
23. D. Chu, M.E. Lacouture, T. Fillos, and S. Wu Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis Acta Oncol 47 2008 176 186
24. G. Scagliotti, S. Novello, and J. von Pawel Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
25. A. Hauschild, S.S. Agarwala, and U. Trefzer Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
26. R. Chopra The Indian scene J Clin Oncol 19 2001 106S 111S
27. G. Agarwal, P.V. Pradeep, V. Aggarwal, C.H. Yip, and P.S. Cheung Spectrum of breast cancer in Asian women World J Surg 31 2007 1031 1040
28. G. Agarwal, and P. Ramakant Breast cancer care in India: the current scenario and the challenges for the future Breast Care 3 2008 21 27
29. J. Bergh, R. Greil, and N. Voytko Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) J Clin Oncol 28 Suppl. 2010 Abstr. LBA1010
30. J. Crown, V. Dieras, and E. Staroslawska Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) J Clin Oncol 28 Suppl. 2010 Abstr. LBA1011